FDA Approves New Drug Labeling for Fludarabine Phosphate in CLL
The FDA has approved revised drug labeling for fludarabine phosphate under Project Renewal.
Related Articles
Harnessing Family Connections to Prevent Hereditary Cancers : Oncology Times
An abstract is unavailable.
Human-centered AI as a framework guiding the development of image-based diagnostic tools in oncology: a systematic review
Artificial intelligence diagnostic tools (AIDTs) in oncology show high image classification accuracy but limited clinical adoption. Their adoption could be enhanced by (i) using user…
Cancer Clinical Trials: A Relevant Need to Clearly Define the Value to Individual Patients
Serious questions must be asked about the current state of interventional trials in the oncology sphere and how to improve their future value.
Ongoing and Planned Research Build on Prior Advancements in ER+/HER2– Breast Cancer
Lubna Naaz Chaudhary, MD, MS, highlights the PARSIFAL and Young-PEARL trials and discusses ongoing research in ER-positive/HER2-negative breast cancer.
I-SPY2 Trial Highlights Treatment for Rare Breast Cancer… : Oncology Times
An abstract is unavailable.
Trials Needed for Sequencing Checkpoint Inhibitors in Bladder Cancer
Petros Grivas, MD, PhD, elaborates on some key unanswered questions on approaches to bladder cancer treatment he discussed with participants at a Case-Based Roundtable event.
Mismatch Repair and Microsatellite Testing for Individuals With Colorectal Cancer
This cohort study examines the institution-level and patient-level factors associated with mismatch repair and microsatellite testing for individuals with colorectal cancer.
Relapsed/Refractory CLL: Which Treatments Are the Safest? – Oncology Nurse Advisor
Researchers found no significant differences in the risk of overall adverse events (AEs), but there were significant differences in grade 3 or higher AEs, serious…
Allogeneic CAR T-Cell Therapy Is Safe, Effective in Heavily Pretreated Myeloma
P-BCMA-ALLO1 elicited high response rates and a manageable safety profile in heavily pretreated, relapsed/refractory multiple myeloma.
